Time Course and Pattern of Blood Loss With Ibuprofen Treatment in Healthy Subjects  Barry Bowen, Yuhong Yuan, Cindy James, Ferid Rashid, Richard H. Hunt  Clinical Gastroenterology and Hepatology  Volume 3, Issue 11, Pages 1075-1082 (November 2005) DOI: 10.1016/S1542-3565(05)00605-1 Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 1 The average and the standard deviation of the mean values for the FBL (mL/day) in the placebo group. STDS, standard deviations. Clinical Gastroenterology and Hepatology 2005 3, 1075-1082DOI: (10.1016/S1542-3565(05)00605-1) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 2 The average and the standard deviation of the mean for the FBL caused by ibuprofen. Both the average FBL and the standard deviation are above 2.5% and as high as 13%. STDS, standard deviations. Clinical Gastroenterology and Hepatology 2005 3, 1075-1082DOI: (10.1016/S1542-3565(05)00605-1) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 3 Pattern and extent of FBL of several subjects in the ibuprofen group. (A) A subject with several significant bleeding episodes with FBL >3 mL <15 mL/day. (B) A subject with 2 significant bleeding episodes with FBL >15 mL/day. (C) A subject with several microbleeding episodes with FBL >2 mL but <3 mL/day. (D) A subject with 4 bleeding episodes FBL > 3 and <8 mL; FBL did not go back to the normal limit throughout the study. Clinical Gastroenterology and Hepatology 2005 3, 1075-1082DOI: (10.1016/S1542-3565(05)00605-1) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 4 FBL of a subject with 1 very large bleeding episode (FBL 66 mL) followed by 3 smaller ones (FBL >3 mL <10 mL). Clinical Gastroenterology and Hepatology 2005 3, 1075-1082DOI: (10.1016/S1542-3565(05)00605-1) Copyright © 2005 American Gastroenterological Association Terms and Conditions